Insider Transactions in Q1 2023 at Altimmune, Inc. (ALT)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2023
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+31.24%
|
$40,000
$4.31 P/Share
|
|
Mar 23
2023
|
David Drutz Director |
BUY
Open market or private purchase
|
Indirect |
9,000
+23.39%
|
$36,000
$4.27 P/Share
|
|
Mar 23
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+23.09%
|
$40,000
$4.22 P/Share
|
|
Feb 02
2023
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,422
-3.27%
|
$126,330
$15.04 P/Share
|
|
Feb 02
2023
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,950
+6.85%
|
-
|
|
Feb 02
2023
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,364
-9.21%
|
$35,460
$15.04 P/Share
|
|
Feb 02
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+23.24%
|
-
|
|
Feb 02
2023
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,375
-10.68%
|
$35,625
$15.04 P/Share
|
|
Feb 02
2023
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+25.91%
|
-
|
|
Feb 01
2023
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,658
-3.11%
|
$99,554
$13.78 P/Share
|
|
Feb 01
2023
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,546
+6.3%
|
-
|
|
Feb 01
2023
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,183
-10.87%
|
$28,379
$13.78 P/Share
|
|
Feb 01
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+23.49%
|
-
|
|
Feb 01
2023
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,183
-13.12%
|
$28,379
$13.78 P/Share
|
|
Feb 01
2023
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+27.04%
|
-
|
|
Jan 31
2023
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,938
+0.84%
|
$19,380
$10.21 P/Share
|
|
Jan 31
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,296
+8.52%
|
$12,960
$10.21 P/Share
|
|
Jan 31
2023
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,436
+12.06%
|
$14,360
$10.21 P/Share
|
|
Jan 31
2023
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,172
+8.89%
|
$11,720
$10.21 P/Share
|